Moderna's cancer vaccine study leaked online, stock crashes
Moderna's stock plunges 25% on Wall Street after details from its cancer vaccine study were leaked online. The decline is expected to be the steepest since its 2018 IPO. Merck's stock falls 1.5%. Moderna and Merck declined to comment.
Moderna's stock is plunging 25% in Wall Street trading after details from the company's confidential mRNA-based cancer vaccine study were circulated on social media. The decline is expected to be the steepest since the company's 2018 IPO. In August, Moderna and its partner Merck announced that the vaccine prevented the recurrence or spread of melanoma, a deadly form of skin cancer. The result was praised, but experts warned that its evaluation was conditional on the release of full data, which was scheduled to be published on Saturday at the ESMO conference. Merck's stock falls 1.5%. According to screenshots circulated on X, the site OncologyCentral published some of the results on Thursday ahead of schedule. Moderna and Merck declined to comment.